Cell line · CVCL_4744
Papers42
1 to 20 of 42
Download this page as JSON| Paper | Journal | Year | How we know | Retracted | Source |
|---|---|---|---|---|---|
| Serotonin Modulates Lineage Plasticity in Neuroendocrine Prostate Cancer via Epigenetic Reprogramming. | Cancer Discov | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Targeting Tumor Microenvironment-Derived NRG1-HER2/3 Signaling with Zenocutuzumab Restores Sensitivity to AR Inhibition in PTEN Wild-type Prostate Cancer. | Mol Cancer Ther | 2026 | Its Methods give the RRID and name the line | PubMed | |
| PRDM16 Regulates Prostate Cancer Cell Dormancy and Prevents Bone Metastatic Outgrowth. | Cancer Res | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Cytomegalovirus infection is common in prostate cancer and antiviral therapies inhibit progression in disease models. | Mol Oncol | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Acute BRCAness induction and AR pathway blockage through CDK12/7/9 degradation enhances PARP inhibitor sensitivity in prostate cancer. | Sci Adv | 2025 | Its Methods give the RRID and name the line | PubMed | |
| CRM1 regulates androgen receptor stability and impacts DNA repair pathways in prostate cancer, independent of the androgen receptor. | FASEB J | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Stimulating Soluble Guanylyl Cyclase with the Clinical Agonist Riociguat Restrains the Development and Progression of Castration-Resistant Prostate Cancer. | Cancer Res | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Development of an orally bioavailable CDK12/13 degrader and induction of synthetic lethality with AKT pathway inhibition. | Cell Rep Med | 2024 | Its Methods give the RRID and name the line | PubMed | |
| A Compound That Inhibits Glycolysis in Prostate Cancer Controls Growth of Advanced Prostate Cancer. | Mol Cancer Ther | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Retinoic acid receptor activation reprograms senescence response and enhances anti-tumor activity of natural killer cells. | Cancer Cell | 2024 | Its Methods give the RRID and name the line | PubMed | |
| ERBB3 Overexpression is Enriched in Diverse Patient Populations with Castration-sensitive Prostate Cancer and is Associated with a Unique AR Activity Signature. | Clin Cancer Res | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Concurrent Targeting of HDAC and PI3K to Overcome Phenotypic Heterogeneity of Castration-resistant and Neuroendocrine Prostate Cancers. | Cancer Res Commun | 2023 | Its Methods give the RRID and name the line | PubMed | |
| Identification of an Imidazopyridine-based Compound as an Oral Selective Estrogen Receptor Degrader for Breast Cancer Therapy. | Cancer Res Commun | 2023 | Its Methods give the RRID and name the line | PubMed | |
| Isocitrate dehydrogenase 1 sustains a hybrid cytoplasmic-mitochondrial tricarboxylic acid cycle that can be targeted for therapeutic purposes in prostate cancer. | Mol Oncol | 2023 | Its Methods give the RRID and name the line | PubMed | |
| Expression and Therapeutic Targeting of TROP-2 in Treatment-Resistant Prostate Cancer. | Clin Cancer Res | 2023 | Its Methods give the RRID and name the line | PubMed | |
| GCN2 eIF2 kinase promotes prostate cancer by maintaining amino acid homeostasis. | Elife | 2022 | Its Methods give the RRID and name the line | PubMed | |
| Reversible epigenetic alterations regulate class I HLA loss in prostate cancer. | Commun Biol | 2022 | Its Methods give the RRID and name the line | PubMed | |
| Proteome profiling of enzalutamide-resistant cell lines and serum analysis identified ALCAM as marker of resistance in castration-resistant prostate cancer. | Int J Cancer | 2022 | Its Methods give the RRID and name the line | PubMed | |
| The long noncoding RNA H19 regulates tumor plasticity in neuroendocrine prostate cancer. | Nat Commun | 2021 | Its Methods give the RRID and name the line | PubMed | |
| AXL cooperates with EGFR to mediate neutrophil elastase-induced migration of prostate cancer cells. | iScience | 2021 | Its Methods give the RRID and name the line | PubMed |
cell-lines-2026-11-14-0.1.0
Sources 4
- CellosaurusCC BY 4.0, with credit to Cellosaurus (SIB)
- PubMed Central's articlesTitles shown only for CC0, CC BY and public domain articles
- NLM's PMC Article DatasetsCourtesy of NLM, which does not endorse this database
- PubMedNLM's terms
Each source's terms
- CellosaurusCC BY 4.0. Cellosaurus's README: "we have chosen to apply the Creative Commons Attribution 4.0 International (CC BY 4.0) license to Cellosaurus (https://creativecommons.org/licenses/by/4.0/). This means that you are free to copy and redistribute Cellosaurus in any medium or format. You can remix, transform, and build upon Cellosaurus for any purpose, even commercially. You must give appropriate credit, provide a link to the license, and indicate if changes were made." Copyright (c) CALIPHO group, SIB Swiss Institute of Bioinformatics. Read on 14 Nov 2026 at https://ftp.expasy.org/databases/cellosaurus/README
- PubMed Central's articlesEach article's own license. Its words show only under CC0, CC BY or public domain
- NLM's PMC Article DatasetsNLM's PMC Article Datasets on AWS, https://registry.opendata.aws/ncbi-pmc. Its terms: users "acknowledge NLM as the source of the data in a clear and conspicuous manner", do not use the PubMed Central wordmark or the PMC logo, do not "indicate or imply that NLM/NIH/HHS has endorsed" a product, and "only distribute data that are licensed for redistribution". Each article keeps its own license: https://pmc.ncbi.nlm.nih.gov/about/copyright/
- PubMedNLM's terms
Cellosaurus, SIB Swiss Institute of Bioinformatics, https://www.cellosaurus.org, CC BY 4.0. Its problem notes are given in its own words.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/cell-lines/v1/CVCL_4744/papers